Skip to main content
Lavipharm S.A. logo

Lavipharm S.A. — Investor Relations & Filings

Ticker · LAVI ISIN · GRS246003008 LEI · 213800USC69CRPRGWJ15 AT Manufacturing
Open in API
Filings indexed 50 across all filing types
Latest filing 2026-06-03 Share Issue/Capital Cha…
Country GR Greece
Listing AT LAVI

About Lavipharm S.A.

https://lavipharm.com/

Lavipharm S.A. is an integrated healthcare company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical products. Established in 1911, the company offers a diverse portfolio that includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements. A key area of innovation for the company is its development of transdermal drug delivery systems. Lavipharm focuses on providing treatment options across several major therapeutic areas, including cardiology, neurology (Central Nervous System), urology, oncology, and chronic pain management.

Recent filings

Filing Released Lang Actions
ΕΙΣΑΓΩΓΗ ΠΡΟΣ ΔΙΑΠΡΑΓΜΑΤΕΥΣΗ ΝΕΩΝ ΚΟΙΝΩΝ ΟΝΟΜΑΣΤΙΚΩΝ ΜΕΤΟΧΩΝ
Share Issue/Capital Change Classification · 92% confidence The document is a formal announcement by Lavipharm’s Board of Directors regarding the implementation of a capital increase, issuance of 1,734,922 new ordinary shares, regulatory approvals and the listing of these shares on Euronext Athens. This fits precisely the description of “Share Issue/Capital Change” filings, which cover new share issues and other capital changes.
2026-06-03 Greek (modern)
ΠΡΟΣΚΛΗΣΗ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a lengthy "Πρόσκληση" (Invitation) to the Annual General Meeting, detailing the meeting date, full agenda (approval of financial statements, governance reports, dividend distribution, board elections, etc.), shareholder participation and proxy voting procedures, and minority shareholder rights under corporate law. It is not the financial statements themselves or a simple publication notice, nor is it a management discussion or earnings release. Instead, it is information sent to shareholders to request their votes and provide the necessary meeting and proxy details. This corresponds to our definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-03 Greek (modern)
Βασικά Οικονομικά Μεγέθη Α’ Τριμήνου 2026
Earnings Release Classification · 95% confidence The document is a ‘Flash Note’ summarizing the Group’s first-quarter 2026 financial performance, with key metrics (EBITDA, net profit, sales breakdown) and simple tables. It serves as an initial public announcement of quarterly results rather than a full interim report or investor slide deck. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-28 Greek (modern)
Key Financial Highlights — First Quarter 2026
Earnings Release Classification · 90% confidence The document is a first quarter 2026 financial summary (“Flash Note”) highlighting key financial metrics (EBITDA, sales, profit, net debt, segment breakdown). It is an initial press‐style announcement of quarterly results with headline numbers and summary tables, not a full interim report. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-28 English
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΧΕΙΡΗΜΑΤΙΚΩΝ ΕΞΕΛΙΞΕΩΝ
Regulatory Filings Classification · 45% confidence The document is a corporate announcement in Greek by Lavipharm regarding the completion of its transaction to acquire product licenses and trademarks (DUROGESIC®) from Janssen Global Services. It is not an AGM material, earnings release, financial report, management change notice, share issue, or formal M&A proxy/tender‐offer filing. Rather, it is a general regulatory announcement of a business transaction. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-05-27 Greek (modern)
STATEMENT
M&A Activity Classification · 85% confidence The document is a press announcement by Lavipharm S.A. stating the completion of a transaction for the acquisition of commercialization rights and trademarks of DUROGESIC® from Janssen. It describes the closing of a business acquisition, not financial results or meeting materials. This falls under M&A-related activity.
2026-05-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.